Zentalis Pharmaceuticals Valuation Multiples

Zentalis Pharmaceuticals is valued at $169M as of November 2026. In the last 12 months, Zentalis Pharmaceuticals EBITDA was ($175M).

Zentalis Pharmaceuticals Overview

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.


Founded

2014

HQ

United States

Employees

166

Financials (LTM)

Revenue: -
EBITDA: ($175M)

EV

$28M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Zentalis Pharmaceuticals Financials

Zentalis Pharmaceuticals reported last 12-month revenue of - and negative EBITDA of ($175M).

In the same LTM period, Zentalis Pharmaceuticals generated - in gross profit, ($175M) in EBITDA losses, and had net loss of ($157M).

Revenue (LTM)


Zentalis Pharmaceuticals P&L

In the most recent fiscal year, Zentalis Pharmaceuticals reported revenue of - and EBITDA of ($136M).

Zentalis Pharmaceuticals is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.

See analyst estimates for Zentalis Pharmaceuticals
LTMLast FY202320242025202620272028
Revenue---$67M-
EBITDA($175M)($136M)($275M)($164M)($136M)
EBITDA Margin---(244%)-
EBIT Margin---(278%)-
Net Profit($157M)($137M)($292M)($166M)($137M)
Net Margin---(246%)-
Net Debt-($291K)---

Financial data powered by Morningstar, Inc.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals has current market cap of $169M, and enterprise value of $28M.

Market Cap Evolution


Zentalis Pharmaceuticals' stock price is $1.72.

Zentalis Pharmaceuticals share price decreased by 12.2% in the last 30 days, and increased by 20.3% in the last year.

Zentalis Pharmaceuticals has an EPS (earnings per share) of $-1.40.

See more trading valuation data for Zentalis Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$28M$169M0.0%-12.2%-54.4%20.3%$-1.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Zentalis Pharmaceuticals Valuation Multiples

Zentalis Pharmaceuticals trades at (0.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Zentalis Pharmaceuticals

EV / Revenue (LTM)


Zentalis Pharmaceuticals Financial Valuation Multiples

As of November 8, 2026, Zentalis Pharmaceuticals has market cap of $169M and EV of $28M.

Zentalis Pharmaceuticals has a P/E ratio of (1.1x).

LTMLast FY202320242025202620272028
EV/Revenue---0.4x-
EV/EBITDA(0.2x)(0.2x)(0.1x)(0.2x)(0.2x)
EV/EBIT(0.2x)(0.2x)(0.1x)(0.1x)(0.2x)
P/E(1.1x)(1.2x)(0.6x)(1.0x)(1.2x)
EV/FCF-(0.2x)(0.1x)(0.2x)(0.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Zentalis Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Zentalis Pharmaceuticals Margins & Growth Rates

Zentalis Pharmaceuticals grew EBITDA by 31% in the last fiscal year.

See estimated margins and future growth rates for Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Margins

2024202720282029
EBITDA Margin(244%)
EBIT Margin(278%)
Net Margin(246%)
FCF Margin(254%)

Zentalis Pharmaceuticals Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth--(100%)-
EBITDA Growth31%(40%)(17%)31%
EBIT Growth18%(26%)(23%)18%
Net Profit Growth17%(43%)(17%)17%
FCF Growth-(18%)(27%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Zentalis Pharmaceuticals Operational KPIs

Zentalis Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.

Access forward-looking KPIs for Zentalis Pharmaceuticals
Last FY2024202620272028
Revenue per Employee$0.0M-
Opex per Employee$0.9M-
G&A Expenses to Revenue-129%
R&D Expenses to Revenue-249%
Opex to Revenue-384%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Zentalis Pharmaceuticals Competitors

Zentalis Pharmaceuticals competitors include Nextbiomedical Co, TYK Medicines, PegBio, PepGen, Invivyd, Compugen, Searle Co., BridgeBio Oncology, Mayne Pharma Group and S Biomedics.

Most Zentalis Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Nextbiomedical Co$12M($260K)12.1x10.2x(568.5x)(39.7x)
TYK Medicines-($40M)--(4.0x)-
PegBio-($31M)--(4.3x)-
PepGen-($88M)--(0.8x)-
Invivyd$53M($50M)0.3x0.2x(0.3x)(0.1x)
Compugen$73M$31M0.8x3.1x1.9x-
Searle Co.$133M$21M1.5x1.4x9.1x5.4x
BridgeBio Oncology-($145M)----

This data is available for Pro users. Sign up to see all Zentalis Pharmaceuticals competitors and their valuation data.

Start Free Trial

Zentalis Pharmaceuticals VC Funding History

Before going public, Zentalis Pharmaceuticals raised $263M in total equity funding, across 3 rounds.


Zentalis Pharmaceuticals Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jul-20Undisclosed stage-$144M--
Dec-19Series CEventide; Redmile Group; Matrix Capital; Viking Global Investors; Surveyor Capital; Perceptive Advisors$85M-Zentalis Pharmaceuticals emerged from stealth in September 2019 with an $85 million Series C financing round led by investors including Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Citadel's Surveyor Capital, and Eventide Asset Management. The funding brought the company's total capital raised to $147 million and was intended to advance its solid tumor programs into pivotal clinical trials, broaden the scope of its clinical programs, and support pipeline expansion. At the time, Zentalis had been operating under the radar for five years since its founding, deliberately delaying public emergence to ensure more mature science beyond early-stage projects. The company's lead programs targeted solid tumors, including ZN-c3 (WEE1 kinase inhibitor), an EGFR inhibitor for lung cancer, and a BCL-2 inhibitor (ZN-d5) for blood cancers planned for clinical entry by mid-2020. Its preclinical pipeline included additional programs for blood cancers and solid tumors. CEO Anthony Sun, formerly a partner at Aisling Capital, emphasized advancing to more mature stages with potential combination therapies. Zentalis had outgrown its initial science center and anticipated reaching nearly 100 employees the following year.
Dec-17Series BMatrix Capital; Viking Global Investors$34M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Zentalis Pharmaceuticals

When was Zentalis Pharmaceuticals founded?Zentalis Pharmaceuticals was founded in 2014.
Where is Zentalis Pharmaceuticals headquartered?Zentalis Pharmaceuticals is headquartered in United States.
How many employees does Zentalis Pharmaceuticals have?As of today, Zentalis Pharmaceuticals has over 166 employees.
Who is the CEO of Zentalis Pharmaceuticals?Zentalis Pharmaceuticals' CEO is Julie M. Eastland.
Is Zentalis Pharmaceuticals publicly listed?Yes, Zentalis Pharmaceuticals is a public company listed on Nasdaq.
What is the stock symbol of Zentalis Pharmaceuticals?Zentalis Pharmaceuticals trades under ZNTL ticker.
When did Zentalis Pharmaceuticals go public?Zentalis Pharmaceuticals went public in 2020.
Who are competitors of Zentalis Pharmaceuticals?Zentalis Pharmaceuticals main competitors include Nextbiomedical Co, TYK Medicines, PegBio, PepGen, Invivyd, Compugen, Searle Co., BridgeBio Oncology, Mayne Pharma Group, S Biomedics.
What is the current market cap of Zentalis Pharmaceuticals?Zentalis Pharmaceuticals' current market cap is $169M.
Is Zentalis Pharmaceuticals profitable?No, Zentalis Pharmaceuticals is not profitable.
What is the current EBITDA of Zentalis Pharmaceuticals?Zentalis Pharmaceuticals has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Zentalis Pharmaceuticals?Current EBITDA multiple of Zentalis Pharmaceuticals is (0.2x).
How many companies Zentalis Pharmaceuticals has acquired to date?Zentalis Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Zentalis Pharmaceuticals has invested to date?Zentalis Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Zentalis Pharmaceuticals

Lists including Zentalis Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial